Financial Results
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.7 pts more than Nifty Microcap 250 and 4.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hester Biosciences reported strong FY26 results with standalone PAT growing 63.7% to INR 521 million from INR 318.42 million in FY25. Consolidated PAT nearly doubled to INR 574.84 million from INR 288.26 million. Standalone revenue grew marginally by 2% to INR 2,921.36 million, while consolidated revenue increased 6.9% to INR 3,325.99 million. The company recorded an exceptional gain of INR 69.96 million on divestment of 43.81% stake in subsidiary Texas Lifesciences Private Limited. The board recommended dividend of INR 11 per share (110%) for FY26. Auditors issued unmodified opinion on both standalone and consolidated financials.
The company delivered robust profit growth driven by segment performance, particularly Poultry Healthcare. The exceptional item from subsidiary divestment boosted standalone PAT. Dividend payout signals management confidence. Positive PAT growth of 63-99% should be viewed favorably by shareholders.